Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Depreciation and Depletion: 2020-2023

Historic Depreciation and Depletion for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Sep 2023 value amounting to $404,000.

  • Insight Molecular Diagnostics' Depreciation and Depletion rose 3.32% to $404,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $1.6 million, marking a year-over-year increase of 24.24%. This contributed to the annual value of $1.5 million for FY2022, which is 81.04% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Depreciation and Depletion stood at $404,000 for Q3 2023, which was down 13.30% from $466,000 recorded in Q4 2022.
  • In the past 5 years, Insight Molecular Diagnostics' Depreciation and Depletion registered a high of $466,000 during Q4 2022, and its lowest value of -$216,000 during Q4 2020.
  • For the 3-year period, Insight Molecular Diagnostics' Depreciation and Depletion averaged around $308,444, with its median value being $287,000 (2022).
  • Data for Insight Molecular Diagnostics' Depreciation and Depletion shows a peak YoY surged of 269.57% (in 2021) over the last 5 years.
  • Over the past 4 years, Insight Molecular Diagnostics' Depreciation and Depletion (Quarterly) stood at -$216,000 in 2020, then skyrocketed by 221.30% to $262,000 in 2021, then spiked by 77.86% to $466,000 in 2022, then climbed by 3.32% to $404,000 in 2023.
  • Its last three reported values are $404,000 in Q3 2023, $466,000 for Q4 2022, and $391,000 during Q3 2022.